deferiprone has been researched along with Neutropenia in 29 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine." | 10.23 | Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. ( Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S, 2024) |
| " Deferiprone is an oral iron chelator approved for use in the United States as a second line agent for the treatment of transfusional iron overload in patients with thalassemia." | 8.95 | Deferiprone for the treatment of transfusional iron overload in thalassemia. ( Belmont, A; Kwiatkowski, JL, 2017) |
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 8.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "Weekly monitoring of absolute neutrophil count (ANC) under deferiprone therapy in thalassemia patients is recommended to avoid agranulocytosis adverse event." | 7.83 | Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy. ( Belen, BF; Özsevik, SN; Polat, M; Soylu, E, 2016) |
| "Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC)." | 7.83 | Deferiprone-induced agranulocytosis: 20 years of clinical observations. ( Connelly, J; Galanello, R; Palmblad, J; Rozova, A; Spino, M; Tricta, F; Uetrecht, J, 2016) |
| "Approximately 6% of patients with thalassemia receiving deferiprone develop neutropenia." | 7.80 | Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count. ( Chan, LL; El-Alfy, MS; El-Beshlawy, AM; Sari, TT; Tricta, F, 2014) |
| "A risk associated with the iron chelator deferiprone is the development of neutropenia or agranulocytosis." | 7.80 | Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis. ( Abdel Rahman, Y; Al Damanhouri, G; Al Hawsawi, Z; Al-Tonbary, Y; Badr, M; Elalfy, M; Elsafy, U; Karakas, Z; Kilinc, Y; Qari, M; Salama, M; Shebl, S; Stilman, A; Toiber Temin, N; Tricta, F; Wali, YA; Yazman, D; Yesilipek, MA, 2014) |
| "Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking." | 7.76 | The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| " Deferiprone is one of a few drugs that are routinely used in medicine for the treatment of iron overload in thalassemic patients." | 7.75 | Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis. ( Abrol, P; Sen, R; Sharma, RK; Tewari, S, 2009) |
| "Non chemotherapy drug-induced agranulocytosis is considered a potentially life-threatening idiosyncratic blood dyscrasia, thought to result from a partly elucidated immune and/or toxic damage on myelopoiesis, due to a multitude of drugs." | 6.46 | Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. ( Papadaki, HA; Pontikoglou, C, 2010) |
| "This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine." | 6.23 | Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. ( Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S, 2024) |
| "The main adverse effect of deferiprone is the development of neutropenia, which occurs via an unknown mechanism." | 5.12 | Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy. ( Athanassiou-Metaxa, M; Haralambidou-Vranitsa, S; Ioannidou-Papagiannaki, E; Klonizakis, I; Perifanis, V; Tziomalos, K; Vlachaki, E, 2007) |
| "Agranulocytosis developed in a 63-year-old patient with myelodysplasia 6 weeks after commencing treatment with the oral iron chelator deferiprone (L1, 1,2-dimethyl-3-hydroxypyrid-4-one, CP20) at a daily dose of 79 mg/kg." | 5.07 | Deferiprone-associated myelotoxicity. ( al-Refaie, FN; Hoffbrand, AV; Wonke, B, 1994) |
| " Deferiprone is an oral iron chelator approved for use in the United States as a second line agent for the treatment of transfusional iron overload in patients with thalassemia." | 4.95 | Deferiprone for the treatment of transfusional iron overload in thalassemia. ( Belmont, A; Kwiatkowski, JL, 2017) |
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 4.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "Data from several trials have provided evidence for the efficacy of deferiprone in the treatment of iron overload in thalassemia major." | 4.79 | Orally active iron chelators in the treatment of iron overload. ( Olivieri, NF, 1996) |
| "Weekly monitoring of absolute neutrophil count (ANC) under deferiprone therapy in thalassemia patients is recommended to avoid agranulocytosis adverse event." | 3.83 | Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy. ( Belen, BF; Özsevik, SN; Polat, M; Soylu, E, 2016) |
| "Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC)." | 3.83 | Deferiprone-induced agranulocytosis: 20 years of clinical observations. ( Connelly, J; Galanello, R; Palmblad, J; Rozova, A; Spino, M; Tricta, F; Uetrecht, J, 2016) |
| "Approximately 6% of patients with thalassemia receiving deferiprone develop neutropenia." | 3.80 | Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count. ( Chan, LL; El-Alfy, MS; El-Beshlawy, AM; Sari, TT; Tricta, F, 2014) |
| "A risk associated with the iron chelator deferiprone is the development of neutropenia or agranulocytosis." | 3.80 | Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis. ( Abdel Rahman, Y; Al Damanhouri, G; Al Hawsawi, Z; Al-Tonbary, Y; Badr, M; Elalfy, M; Elsafy, U; Karakas, Z; Kilinc, Y; Qari, M; Salama, M; Shebl, S; Stilman, A; Toiber Temin, N; Tricta, F; Wali, YA; Yazman, D; Yesilipek, MA, 2014) |
| "Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking." | 3.76 | The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| " Deferiprone is one of a few drugs that are routinely used in medicine for the treatment of iron overload in thalassemic patients." | 3.75 | Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis. ( Abrol, P; Sen, R; Sharma, RK; Tewari, S, 2009) |
| "In previous trials, the orally active iron chelator deferiprone (L1) has been associated with sporadic agranulocytosis, milder forms of neutropenia and other side-effects." | 3.70 | Safety profile of the oral iron chelator deferiprone: a multicentre study. ( Cohen, AR; Dipalma, A; Galanello, R; Piga, A; Tricta, F; Vullo, C, 2000) |
| "In participants with early Parkinson's disease who had never received levodopa and in whom treatment with dopaminergic medications was not planned, deferiprone was associated with worse scores in measures of parkinsonism than those with placebo over a period of 36 weeks." | 3.11 | Trial of Deferiprone in Parkinson's Disease. ( Ayton, S; Behnke, S; Berg, D; Bloem, BR; Bordet, R; Bush, AI; Cabantchik, I; Carpentier, J; Chupin, M; Coelho, MVS; Compta, Y; Corvol, JC; de Bie, RMA; Defebvre, L; Deplanque, D; Devedjian, JC; Devos, D; Dexter, DT; Dodel, R; Duce, JA; Duhamel, A; Dušek, P; Eusebio, A; Ferreira, J; Fradette, C; Gago, M; Garçon, G; Guyon Delannoy, P; Habert, MO; Januario, C; Kuchcinski, G; Kulisevsky, J; Labreuche, J; Leclercq, C; Lehericy, S; Lopes, R; Maetzler, W; Mangin, JF; Marques, AR; Meissner, WG; Moreau, C; Nyholm, D; Ory-Magne, F; Otto, M; Ouk, T; Pavese, N; Pigny, P; Poewe, W; Post, B; Potey, C; Pruvo, JP; Rascol, O; Rolland, AS; Růžička, E; Scherfler, C; Seppi, K; Simonin, O; Spino, M; Thobois, S; Tranchant, C; Tricta, F; Viard, R; Vilas, D; Walter, U; Worth, P, 2022) |
| "In patients with thalassemia intermedia (TI), such as beta-TI, alpha-thalassemia (mainly HbH disease and mild/moderate forms of HbE/beta-thalassemia), iron overload is an important challenge in terms of diagnosis, monitoring, and treatment." | 2.80 | Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. ( Calvaruso, G; Colletta, G; Di Maggio, R; Gerardi, C; Lai, E; Maggio, A; Pitrolo, L; Quota, A; Rigoli, LC; Sacco, M; Vitrano, A, 2015) |
| "Enrolled patients (9 with β-thalassemia major and 33 with β-thalassemia hemoglobin E), ranging from 3 to 18 years in age, were divided into 3 groups; group 1 ferritin ≥1,000-2,500 ng/ml (n = 10), group 2 ferritin >2,500-4,000 ng/ml (n = 23) and group 3 ferritin >4,000 ng/ml (n = 9)." | 2.80 | Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience. ( Chuansumrit, A; Kadegasem, P; Sasanakul, W; Sirachainan, N; Songdej, D; Sungkarat, W; Wongwerawattanakoon, P, 2015) |
| "Thrombocytopenia is one of the major side effects in young thalassaemics and necessitates frequent close monitoring of blood counts but its resolution after discontinuation and absence of clinical evidence of bleeding does not preclude its use." | 2.71 | Safety of oral iron chelator deferiprone in young thalassaemics. ( Chandra, J; Naithani, R; Sharma, S, 2005) |
| "The rates of agranulocytosis (absolute neutrophil count [ANC] < 500 x 10(9)/L) and milder forms of neutropenia (ANC, 500-1500 x 10(9)/L) were 0." | 2.71 | Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. ( Cohen, AR; De Sanctis, V; Galanello, R; Piga, A; Tricta, F, 2003) |
| " These data show that the drug was effective in reducing serum ferritin levels and the incidence of adverse events was not greater than the frequency reported in clinical trials." | 2.70 | The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. ( Baiardi, P; Cappellini, MD; Carnelli, V; Ceci, A; De Sanctis, V; Felisi, M; Galanello, R; Maggio, A; Masera, G; Piga, A; Schettini, F; Stefàno, I; Tricta, F, 2002) |
| "The sporadic occurrence of agranulocytosis in association with deferiprone and the highly variable frequency of other possible side effects such as arthralgia have created uncertainty about the true incidence of deferiprone-related complications." | 2.69 | A multi-center safety trial of the oral iron chelator deferiprone. ( Cohen, A; Galanello, R; Piga, A; Tricta, F; Vullo, C, 1998) |
| " During the course of the trial, several possible adverse effects have been encountered." | 2.67 | Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. ( al-Refaie, FN; Hoffbrand, AV; Kontoghiorghes, GJ; Nortey, P; Wickens, DG; Wonke, B, 1992) |
| "Non chemotherapy drug-induced agranulocytosis is considered a potentially life-threatening idiosyncratic blood dyscrasia, thought to result from a partly elucidated immune and/or toxic damage on myelopoiesis, due to a multitude of drugs." | 2.46 | Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. ( Papadaki, HA; Pontikoglou, C, 2010) |
| "There is a lack of knowledge regarding the incidence of serious adverse drug reactions (ADR) to the oral iron chelator deferiprone in Chinese children with transfusion-dependent thalassaemia." | 1.43 | Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia. ( Botzenhardt, S; Ceci, A; Chan, GC; Felisi, M; Neubert, A; Rascher, W; Sing, CW; Wong, IC; Wong, LY, 2016) |
| "Deferiprone (L1) has been used in several countries for iron chelation therapy for over one decade." | 1.36 | Long-term response to deferiprone therapy in Asian Indians. ( Das, RR; Marwaha, RK; Panigrahi, I, 2010) |
| "Deferiprone (L1) was discontinued as it was suspected to be the offending agent and prompt broad-spectrum antibiotic therapy was initiated after which the patient improved." | 1.34 | Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient. ( Inati, A; Koussa, S; Sheikh-Taha, M; Taher, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (20.69) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 11 (37.93) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Devos, D | 3 |
| Labreuche, J | 3 |
| Rascol, O | 3 |
| Corvol, JC | 3 |
| Duhamel, A | 3 |
| Guyon Delannoy, P | 3 |
| Poewe, W | 3 |
| Compta, Y | 3 |
| Pavese, N | 3 |
| Růžička, E | 3 |
| Dušek, P | 3 |
| Post, B | 3 |
| Bloem, BR | 3 |
| Berg, D | 3 |
| Maetzler, W | 3 |
| Otto, M | 3 |
| Habert, MO | 3 |
| Lehericy, S | 3 |
| Ferreira, J | 3 |
| Dodel, R | 3 |
| Tranchant, C | 3 |
| Eusebio, A | 3 |
| Thobois, S | 3 |
| Marques, AR | 3 |
| Meissner, WG | 3 |
| Ory-Magne, F | 3 |
| Walter, U | 3 |
| de Bie, RMA | 3 |
| Gago, M | 3 |
| Vilas, D | 3 |
| Kulisevsky, J | 3 |
| Januario, C | 3 |
| Coelho, MVS | 3 |
| Behnke, S | 3 |
| Worth, P | 3 |
| Seppi, K | 3 |
| Ouk, T | 3 |
| Potey, C | 3 |
| Leclercq, C | 3 |
| Viard, R | 3 |
| Kuchcinski, G | 3 |
| Lopes, R | 3 |
| Pruvo, JP | 3 |
| Pigny, P | 3 |
| Garçon, G | 3 |
| Simonin, O | 3 |
| Carpentier, J | 3 |
| Rolland, AS | 3 |
| Nyholm, D | 3 |
| Scherfler, C | 3 |
| Mangin, JF | 3 |
| Chupin, M | 3 |
| Bordet, R | 3 |
| Dexter, DT | 3 |
| Fradette, C | 4 |
| Spino, M | 4 |
| Tricta, F | 11 |
| Ayton, S | 3 |
| Bush, AI | 3 |
| Devedjian, JC | 3 |
| Duce, JA | 3 |
| Cabantchik, I | 3 |
| Defebvre, L | 3 |
| Deplanque, D | 3 |
| Moreau, C | 3 |
| Hamdy, M | 1 |
| El-Beshlawy, A | 1 |
| Veríssimo, MPA | 1 |
| Kanter, J | 1 |
| Inusa, B | 1 |
| Williams, S | 1 |
| Lee, D | 1 |
| Temin, NT | 1 |
| Ebeid, FSE | 1 |
| Kwiatkowski, JL | 2 |
| Elalfy, MS | 1 |
| Belmont, A | 1 |
| El-Beshlawy, AM | 1 |
| El-Alfy, MS | 1 |
| Sari, TT | 1 |
| Chan, LL | 1 |
| Elalfy, M | 1 |
| Wali, YA | 1 |
| Qari, M | 1 |
| Al Damanhouri, G | 1 |
| Al-Tonbary, Y | 1 |
| Yazman, D | 1 |
| Al Hawsawi, Z | 1 |
| Karakas, Z | 1 |
| Kilinc, Y | 1 |
| Yesilipek, MA | 1 |
| Badr, M | 1 |
| Elsafy, U | 1 |
| Salama, M | 1 |
| Abdel Rahman, Y | 1 |
| Shebl, S | 1 |
| Stilman, A | 1 |
| Toiber Temin, N | 1 |
| Songdej, D | 1 |
| Sirachainan, N | 1 |
| Wongwerawattanakoon, P | 1 |
| Sasanakul, W | 1 |
| Kadegasem, P | 1 |
| Sungkarat, W | 1 |
| Chuansumrit, A | 1 |
| Calvaruso, G | 1 |
| Vitrano, A | 1 |
| Di Maggio, R | 1 |
| Lai, E | 1 |
| Colletta, G | 1 |
| Quota, A | 1 |
| Gerardi, C | 1 |
| Rigoli, LC | 1 |
| Sacco, M | 1 |
| Pitrolo, L | 1 |
| Maggio, A | 2 |
| Botzenhardt, S | 1 |
| Sing, CW | 1 |
| Wong, IC | 1 |
| Chan, GC | 1 |
| Wong, LY | 1 |
| Felisi, M | 2 |
| Rascher, W | 1 |
| Ceci, A | 2 |
| Neubert, A | 1 |
| Belen, BF | 1 |
| Polat, M | 1 |
| Özsevik, SN | 1 |
| Soylu, E | 1 |
| Uetrecht, J | 1 |
| Galanello, R | 6 |
| Connelly, J | 1 |
| Rozova, A | 1 |
| Palmblad, J | 1 |
| Panigrahi, I | 1 |
| Marwaha, RK | 1 |
| Das, RR | 1 |
| Tewari, S | 2 |
| Sharma, RK | 1 |
| Abrol, P | 1 |
| Sen, R | 1 |
| Pontikoglou, C | 1 |
| Papadaki, HA | 1 |
| Ricchi, P | 1 |
| Ammirabile, M | 1 |
| Costantini, S | 1 |
| Cinque, P | 1 |
| Lanza, AG | 1 |
| Spasiano, A | 1 |
| Di Matola, T | 1 |
| Di Costanzo, G | 1 |
| Pagano, L | 1 |
| Prossomariti, L | 1 |
| Cohen, AR | 2 |
| Piga, A | 5 |
| De Sanctis, V | 2 |
| Naithani, R | 1 |
| Chandra, J | 1 |
| Sharma, S | 1 |
| Roggero, S | 1 |
| Vinciguerra, T | 1 |
| Sacchetti, L | 1 |
| Gallo, V | 1 |
| Longo, F | 1 |
| Vlachaki, E | 1 |
| Ioannidou-Papagiannaki, E | 1 |
| Tziomalos, K | 1 |
| Haralambidou-Vranitsa, S | 1 |
| Perifanis, V | 1 |
| Klonizakis, I | 1 |
| Athanassiou-Metaxa, M | 1 |
| Tanner, MA | 1 |
| Dessi, C | 1 |
| Smith, GC | 1 |
| Westwood, MA | 1 |
| Agus, A | 1 |
| Roughton, M | 1 |
| Assomull, R | 1 |
| Nair, SV | 1 |
| Walker, JM | 1 |
| Pennell, DJ | 1 |
| Sheikh-Taha, M | 1 |
| Koussa, S | 1 |
| Inati, A | 1 |
| Taher, A | 1 |
| Adhikari, D | 1 |
| al-Refaie, FN | 2 |
| Wonke, B | 2 |
| Hoffbrand, AV | 2 |
| Olivieri, NF | 1 |
| Cohen, A | 1 |
| Vullo, C | 2 |
| Pati, HP | 1 |
| Choudhry, VP | 1 |
| Dipalma, A | 1 |
| Richardson, DR | 1 |
| Baiardi, P | 1 |
| Cappellini, MD | 1 |
| Carnelli, V | 1 |
| Masera, G | 1 |
| Schettini, F | 1 |
| Stefàno, I | 1 |
| Wickens, DG | 1 |
| Nortey, P | 1 |
| Kontoghiorghes, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for deferiprone and Neutropenia
| Article | Year |
|---|---|
Deferiprone for the treatment of transfusional iron overload in thalassemia.
Topics: Deferiprone; Erythrocyte Transfusion; Humans; Iron; Iron Overload; Myocardium; Neutropenia; Pyridone | 2017 |
Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.
Topics: Agranulocytosis; Deferiprone; Humans; Iron Chelating Agents; Neutropenia; Pyridones | 2010 |
Deferiprone: New insight.
Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St | 2005 |
Orally active iron chelators in the treatment of iron overload.
Topics: Administration, Oral; Agranulocytosis; Chelation Therapy; Clinical Trials as Topic; Deferiprone; Hum | 1996 |
The controversial role of deferiprone in the treatment of thalassemia.
Topics: Agranulocytosis; Arthralgia; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Comb | 2001 |
13 trials available for deferiprone and Neutropenia
| Article | Year |
|---|---|
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression | 2022 |
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression | 2022 |
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression | 2022 |
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression | 2022 |
Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Humans; Iron; Iron C | 2024 |
Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience.
Topics: Administration, Oral; Adolescent; Alanine Transaminase; beta-Thalassemia; Child; Child, Preschool; C | 2015 |
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2015 |
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
Topics: Administration, Oral; Adolescent; Adult; Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Ch | 2003 |
Safety of oral iron chelator deferiprone in young thalassaemics.
Topics: Blood Cell Count; Child; Child, Preschool; Deferiprone; Female; Follow-Up Studies; Humans; Iron Chel | 2005 |
Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Female; Granulocyte Colony-St | 2007 |
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2007 |
Deferiprone-associated myelotoxicity.
Topics: Adult; Agranulocytosis; Deferiprone; Female; Hematopoiesis; Humans; Iron Chelating Agents; Male; Mid | 1994 |
A multi-center safety trial of the oral iron chelator deferiprone.
Topics: Administration, Oral; Adolescent; Adult; Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Ch | 1998 |
Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience.
Topics: Adolescent; beta-Thalassemia; Child; Deferiprone; Female; Humans; India; Iron Chelating Agents; Male | 1999 |
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients.
Topics: Adolescent; Adult; Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Blood Transfusion; Child | 2002 |
Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
Topics: Adult; Deferiprone; Deferoxamine; Female; Ferritins; Follow-Up Studies; Humans; Iron; Iron Chelating | 1992 |
11 other studies available for deferiprone and Neutropenia
| Article | Year |
|---|---|
Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count.
Topics: beta-Thalassemia; Child; Child, Preschool; Deferiprone; Female; Humans; Iron Chelating Agents; Leuko | 2014 |
Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
Topics: Adolescent; Adult; Agranulocytosis; Blood Transfusion; Child; Child, Preschool; Deferiprone; Female; | 2014 |
Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.
Topics: Administration, Oral; Adolescent; Adverse Drug Reaction Reporting Systems; Agranulocytosis; Blood Tr | 2016 |
Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy.
Topics: Adolescent; Anemia, Aplastic; Anemia, Hemolytic; Blood Transfusion; Bone Marrow Diseases; Bone Marro | 2016 |
Deferiprone-induced agranulocytosis: 20 years of clinical observations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Agranulocytosis; Child; Child, Preschool; Clinical Trial | 2016 |
Long-term response to deferiprone therapy in Asian Indians.
Topics: Adolescent; Adult; Agranulocytosis; Asian People; Chelation Therapy; Child; Child, Preschool; Deferi | 2010 |
Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis.
Topics: Adolescent; Agranulocytosis; Alveolar Process; beta-Thalassemia; Blood Transfusion; Deferiprone; Dia | 2009 |
The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.
Topics: Adult; Agranulocytosis; Antiviral Agents; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, | 2010 |
Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.
Topics: Adult; Agranulocytosis; beta-Thalassemia; Blood Transfusion; Deferiprone; Female; Humans; Intracrani | 2007 |
Deferiprone in iron overload.
Topics: Deferiprone; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Joint Diseases; Neutropenia; | 1995 |
Safety profile of the oral iron chelator deferiprone: a multicentre study.
Topics: Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Deferiprone; Gastrointestinal Diseases; Hum | 2000 |